Clinical trials
Nasopharyngeal Carcinoma trials in Taiwan
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
30 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 2 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2010 | 2 |
| 2011 | 1 |
| 2014 | 3 |
| 2015 | 4 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 2 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 11 |
| Unknown status | 9 |
| Terminated | 5 |
| Active, not recruiting | 4 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Taichung Veterans General Hospital | 6 |
| National Health Research Institutes, Taiwan | 4 |
| Chang Gung Memorial Hospital | 3 |
| National Taiwan University Hospital | 3 |
| Novartis Pharmaceuticals | 3 |
| BeiGene | 1 |
| Celgene | 1 |
| China Medical University Hospital | 1 |
| Far Eastern Memorial Hospital | 1 |
| NRG Oncology | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Nasopharyngeal Carcinoma | 30 |
| Epstein-Barr Virus Infections | 7 |
| Nasopharyngeal Neoplasms | 5 |
| Neoplasms | 5 |
| Carcinoma, Non-Small-Cell Lung | 4 |
| Recurrence | 4 |
| Head and Neck Neoplasms | 3 |
| Squamous Cell Carcinoma of Head and Neck | 3 |
| Triple Negative Breast Neoplasms | 3 |
| Melanoma | 2 |
Trials
Showing 1 to 25 of 30. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.